| Literature DB >> 17070906 |
Don M Benson1, Patrick J Elder, Thomas S Lin, William Blum, Sam Penza, Belinda Avalos, Edward Copelan, Sherif S Farag.
Abstract
High-dose chemotherapy (HDC) with autologous stem cell transplant (ASCT) has improved response rates and survival for patients with multiple myeloma (MM). We report a single-institution experience using two conditioning regimens, busulfan, cyclophosphamide, and etoposide (BCV) or high-dose melphalan (HDM). Between July 1992 and August 2003, 110 patients with MM (median age=56.1) underwent HDC with ASCT using either BCV (n=62) or HDM (n=48) in sequential cohorts as the preparative regimen. Overall response rates, progression-free survival, and median overall survival were similar. BCV and HDM confer similar long-term outcomes with similar toxicity profiles as conditioning regimens prior to autologous stem cell transplant in patients with MM.Entities:
Mesh：
Substances：
Year: 2006 PMID： 17070906 DOI： 10.1016/j.leukres.2006.09.021
Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156